KL and lung adenocarcinoma: In conclusion, this retrospective analysis of the phase III JUNIPER trial identified the KL subtype as a candidate predictive biomarker for abemaciclib efficacy in platinum-refractory KRAS-mutant lung adenocarcinoma.